Sarissa Capital (IRWD) cuts Ironwood stake with 6.7M-share sale, keeps 5.8%
Sarissa Capital Management LP and Alexander J. Denner have reduced their stake in Ironwood Pharmaceuticals (IRWD) through the sale of 6.7 million shares on March 17, 2026, for over $20.5 million. Despite the significant sale, Sarissa Capital still beneficially owns 5.6% of Ironwood's outstanding shares, while Alexander J. Denner holds approximately 5.8%, including shares received as director compensation. The transactions were reported in an amended Schedule 13D filing, indicating a notable reduction in position size by an active holder while maintaining a substantial stake.
Ironwood Pharmaceuticals director Denner sells $20.5m in shares
Ironwood Pharmaceuticals director Alexander J. Denner sold $20.5 million worth of Class A Common Stock on March 17, 2026, amidst recent stock volatility. Despite this insider sale, InvestingPro analysis suggests the stock is undervalued, and analysts like Jefferies and Citizens have raised their price targets for IRWD following the company's Q4 2025 earnings report and reaffirmed 2026 guidance. The company also confirmed it met the liquidity conditions for its Credit Agreement.
Ironwood Pharmaceuticals director Denner sells $20.5m in shares By Investing.com
Ironwood Pharmaceuticals director Alexander J. Denner sold $20.5 million worth of Class A Common Stock on March 17, 2026, amidst recent stock volatility but a significant yearly gain. Despite the insider sale, InvestingPro analysis indicates the stock is undervalued, and several analysts have recently raised price targets for the company, citing strong Linzess sales and reaffirmed 2026 guidance. Ironwood also reported meeting liquidity conditions under its Credit Agreement.
Sarissa funds trim Ironwood (NASDAQ: IRWD) stake with 6.7M-share sale
Investment vehicles advised by Sarissa Capital Management LP, associated with director Alexander J. Denner, sold off 6.7 million shares of Ironwood Pharmaceuticals (NASDAQ: IRWD) Class A Common Stock on March 17, 2026, at prices between $3.05 and $3.31 per share. This major sale significantly reduced their indirect holdings, though they still retain over 9 million shares. Separately, Dr. Denner received a smaller equity grant of 4,451 shares, bringing his direct holdings to 256,309.
Ironwood Pharmaceuticals (IRWD) CFO receives 136,612-share stock grant
Ironwood Pharmaceuticals (IRWD) CFO Gregory S. Martini received an equity compensation grant of 136,612 shares of Class A Common Stock on March 10, 2026. This award is in the form of restricted stock units, vesting in four equal installments over approximate anniversaries of the grant date. Following this transaction, Martini directly holds 297,213 shares of Class A Common Stock, as detailed in the SEC Form 4 filing.
Ironwood (NASDAQ: IRWD) CCO granted 136,612 restricted shares as equity award
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) Chief Commercial Officer Tammi L. Gaskins was granted 136,612 restricted shares of Class A Common Stock as an equity award. This compensation award vests in four equal annual installments, tying the value to continued service and performance. Following this grant, Ms. Gaskins' direct holdings increased to 350,350 shares.
Ironwood (NASDAQ: IRWD) CEO receives 409,836-share restricted stock award
Ironwood Pharmaceuticals (NASDAQ: IRWD) CEO Thomas A. McCourt was granted a restricted stock unit award of 409,836 shares of Class A Common Stock. This annual performance award, valued at $0 per share, vests in three equal installments on each approximate anniversary of the grant. Following this transaction, McCourt directly holds 1,898,838 shares of Class A Common Stock.
Ironwood Pharmaceuticals (IRWD) CLO receives 136,612-share RSU grant
John Minardo, the Chief Legal Officer of Ironwood Pharmaceuticals (IRWD), was granted 136,612 shares of Class A Common Stock as a restricted stock unit award. This award, part of his annual performance compensation, vests in four equal installments annually. Following this grant, Minardo directly holds a total of 500,498 shares of the company's Class A Common Stock.
Ironwood (IRWD) accounting chief granted 163,934 RSUs in stock award
Ironwood Pharmaceuticals' principal accounting officer, Ronald Silver, received a grant of 163,934 restricted stock units (RSUs) as part of a stock-based compensation award. This grant, with a value of $0 per share, vests in four equal annual installments and increases his direct holdings to 416,570 shares. The transaction was reported in an SEC Form 4 filing, indicating it was a compensation award rather than an open-market purchase.
Ironwood (IRWD) SVP and CMO awarded 136,612-share RSU performance grant
Michael Shetzline, Senior Vice President and Chief Medical Officer at Ironwood Pharmaceuticals (IRWD), has been granted 136,612 shares of Class A Common Stock as a performance-related restricted stock unit award. This grant, which has no purchase price, will vest in 25% increments annually, increasing his direct ownership to 658,037 shares. The Form 4 filing confirmed this grant does not involve any share sales and is purely compensation.
Ironwood (NASDAQ: IRWD) confirms revolving credit facility maturity in 2028
Ironwood Pharmaceuticals (NASDAQ: IRWD) has confirmed that the maturity date for its revolving credit facility remains December 31, 2028. This confirmation follows the company's notification to Wells Fargo Bank, National Association, the administrative agent, that it has satisfied the liquidity conditions as defined in its Credit Agreement. The 8-K filing indicates a moderate impact and neutral sentiment regarding this event.
Ironwood Pharmaceuticals, Inc. 8-K SEC Filing Details – Company Information, Address, and Nasdaq Listing
Ironwood Pharmaceuticals, Inc. filed a routine 8-K with the SEC announcing a reportable event dated March 10, 2026. The filing provides standard company details, confirms no amendments or material changes, and indicates no price-sensitive information. It serves primarily for regulatory compliance without impacting share value.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Recommendation of "Hold" from Brokerages
Ironwood Pharmaceuticals (NASDAQ:IRWD) has received an average "Hold" recommendation from eight brokerages, with an average one-year price target of $4.93. This comes despite a Q4 earnings miss and pipeline setbacks for apraglutide, which led to a share drop and revised 2026 guidance. However, significant institutional investors have increased their positions in the company, signaling continued interest despite recent challenges.
Ironwood Pharmaceuticals (IRWD) Margin Rebound Challenges Bearish Narratives Despite Softer Revenue
Ironwood Pharmaceuticals (IRWD) closed FY 2025 with mixed Q4 results, showing a revenue decline but an improved net margin of 8.1%. While some see the firming margins and a significant valuation gap against DCF fair value as positive indicators for their GI and rare disease franchises, others highlight concerns over negative shareholders' equity, debt coverage by operating cash flow, and a non-recurring loss affecting profitability. The article suggests investors carefully evaluate these mixed signals to form their own view, particularly concerning the sustainability of the margin improvements amidst projected revenue declines and balance sheet pressures.
[Form 4] IRONWOOD PHARMACEUTICALS INC Insider Trading Activity
Ironwood Pharmaceuticals SVP and CMO Michael Shetzline reported the automatic sale of 32,582 shares across two transactions at weighted average prices of $3.81 and $3.66 per share. These sales were non-discretionary, executed solely to cover tax withholding obligations associated with the vesting of restricted stock units. Following these sales, Shetzline beneficially owned 521,425 shares of Class A Common Stock.
Ironwood (NASDAQ: IRWD) chief auto-sells 36,492 shares for tax withholding
Ironwood Pharmaceuticals' Chief Legal Officer, John Minardo, automatically sold 36,492 shares of Class A common stock to cover tax withholding obligations from vested restricted stock units. These non-discretionary transactions occurred on February 23 and 24, 2026, at weighted average prices of $3.81 and $3.66 per share. Following these sales, Minardo directly holds 363,886 Ironwood shares.
Earnings call transcript: Ironwood Pharmaceuticals Q4 2025 misses forecasts, shares drop
Ironwood Pharmaceuticals (IRWD) reported a significant miss on both Q4 2025 EPS and revenue forecasts, leading to a 16.62% drop in pre-market trading. Despite the setback, the company reiterated its 2026 guidance, expecting substantial sales growth for LINZESS and a significant reduction in debt. Ironwood plans to initiate a confirmatory Phase 3 clinical trial (STARS-2) for its drug apraglutide in Q2 2026, aiming for NDA submission by the end of 2029.
Ironwood Pharmaceuticals (NASDAQ: IRWD) proposes resale of RSU-derived shares
Ironwood Pharmaceuticals (NASDAQ: IRWD) has filed a Form 144, proposing the resale of Class A common stock that originated from restricted stock unit (RSU) awards. The filing details several RSU grant dates ranging from 2022 to 2025, with example share quantities, but does not provide specific timing for the sales or aggregate proceeds. This action indicates an intent to sell shares under Rule 144 procedures, subject to holding period and volume limitations.
Insights into Ironwood Pharmaceuticals's Upcoming Earnings
Ironwood Pharmaceuticals (NASDAQ: IRWD) is set to release its quarterly earnings on February 25, 2026, with analysts forecasting an EPS of $0.01. Investors are keen on positive guidance and to see if the company can surpass estimates, especially considering its past performance of beating EPS forecasts which led to a significant stock price increase. The company's shares have risen 114.04% over the last 52 weeks, indicating a bullish sentiment among long-term shareholders ahead of the earnings call.
Ironwood Pharmaceuticals (NASDAQ: IRWD) reports proposed RSU sales via Form 144
Ironwood Pharmaceuticals has filed a Form 144 detailing proposed sales of Class A common stock derived from restricted stock unit (RSU) awards. These awards, granted under the company's 2019 Equity Incentive Plan, include various share amounts with grant dates spanning from 2022 to 2025. The filing serves as a notification regarding intended Rule 144 sales procedures for these securities.
Ironwood Pharmaceuticals (NASDAQ: IRWD) lists RSU-linked blocks of Class A shares in Form 144
Ironwood Pharmaceuticals has filed a Form 144, indicating proposed sales of Class A Common Stock associated with various restricted stock unit (RSU) awards. The filing lists blocks of shares from RSU awards granted between 2022 and 2025, which are subject to vesting requirements under the company's equity incentive plans. This is a routine administrative filing that does not disclose sale prices, purchasers, or the final timing of any transactions.
[SCHEDULE 13G/A] IRONWOOD PHARMACEUTICALS INC Amended Passive Investment Disclosure
Armistice Capital and Steven Boyd have filed a Schedule 13G/A, disclosing a 9.85% beneficial stake in Ironwood Pharmaceuticals (IRWD), representing 16,025,000 shares of Class A common stock as of December 31, 2025. Armistice Capital, as the investment manager for Armistice Capital Master Fund Ltd., holds shared voting and dispositive power over these shares, with the Master Fund being the direct holder. This amendment signifies a routine passive investment disclosure without intent to influence company control.
Breakthrough And Pullback | Breakout Stocks Deserve Close Attention: STRL, XMTR And HAS
This article identifies breakout stocks Sterling Infrastructure Inc. (STRL), Xometry, Inc. (XMTR), and Sally Beauty Holdings, Inc. (SBH) based on their quantitative analysis model. The analysis focuses on technical breakthroughs or pullbacks to key moving averages, utilizing metrics like Relative Price Strength (RPS) and financial data. The article also provides a market sentiment overview, noting a slight decrease in overall market index scores.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Rating of "Moderate Buy" by Analysts
Ironwood Pharmaceuticals (NASDAQ:IRWD) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $3.68. Several brokerages, including Wells Fargo and Citizens JMP, recently upgraded their ratings and raised price targets. The company beat Q3 earnings and revenue expectations, and institutional buying has significantly increased, indicating strong investor confidence despite recent stock fluctuations.
Universal Beteiligungs und Servicegesellschaft mbH Lowers Stock Holdings in Ironwood Pharmaceuticals, Inc. $IRWD
Universal Beteiligungs und Servicegesellschaft mbH significantly reduced its stake in Ironwood Pharmaceuticals (NASDAQ:IRWD) by 76.3% in the third quarter of 2025, selling 401,900 shares and retaining 124,875 shares valued at $164,000. Despite this, analyst sentiment remains largely positive, with several firms upgrading IRWD to "strong-buy" or "outperform," resulting in a consensus "Moderate Buy" rating and an average target price of $3.68. Ironwood Pharmaceuticals recently reported stronger-than-expected earnings for the quarter, with an EPS of $0.24 against a $0.09 consensus and revenue of $122.06 million, surpassing expectations of $74.22 million.
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) Fits the Minervini High-Growth Momentum Trend Template
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) is presented as a strong candidate fitting Mark Minervini's "Trend Template" and "High Growth Momentum" criteria. The stock demonstrates technical strength with its price above key moving averages and high relative strength, coupled with robust fundamental growth including 1100% EPS growth and positive analyst revisions. Despite a high overall technical rating, the article notes a lower setup quality for immediate purchase, suggesting waiting for price stability.
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Up 8.4% - Here's Why
Ironwood Pharmaceuticals (NASDAQ:IRWD) saw its shares jump 8.4% on Wednesday following a strong earnings report that beat analyst expectations for both EPS and revenue. The company also received several analyst upgrades and higher price targets, leading to a "Moderate Buy" consensus rating. Despite light trading volume, the positive sentiment reflects investor confidence in the company's recent performance and future outlook.
Ironwood Pharmaceuticals (IRWD) price target increased by 94.00% to 4.95
This article reports that the price target for Ironwood Pharmaceuticals (IRWD) has been increased by 94.00%, raising it to $4.95. No other details are provided in the current content.
This drugmaker cut a list price — and still expects higher 2026 sales
Ironwood Pharmaceuticals (IRWD) announced its financial guidance for full-year 2026, expecting LINZESS U.S. net sales of $1.125 to $1.175 billion and adjusted EBITDA greater than $300 million, despite lowering the LINZESS list price. The company maintains its 2025 financial guidance and plans to initiate a confirmatory Phase 3 trial for apraglutide in early 2026 for short bowel syndrome. The anticipated increase in net sales for LINZESS in 2026 is attributed to the elimination of the inflationary component of statutory rebates following the price decrease.
Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating
Ironwood Pharmaceuticals saw its stock rally significantly after releasing 2026 financial guidance that far exceeded analyst expectations, projecting revenues 40% higher than anticipated. This unexpected performance was driven by a strategic decision to cut the list price of its drug LINZESS, which eliminated large rebate penalties and improved net revenue. The increased cash flow will also fully fund the upcoming Phase 3 trials for its pipeline asset apraglutide, removing a key area of investor uncertainty.
Why Ironwood Pharmaceuticals (IRWD) Is Up 37.8% After New 2026 Guidance And Ferring Settlement
Ironwood Pharmaceuticals (IRWD) saw its stock rise 37.8% following the maintenance of its 2025 earnings guidance, new 2026 revenue guidance of US$450 to US$475 million, and a settlement with Ferring regarding a license agreement. The settlement resolves legal uncertainties around VectivBio's licensed products, simplifying commercialization. The article suggests that while the new guidance supports the long-term investment narrative, ongoing regulatory progress for apraglutide and risks related to LINZESS reimbursement and debt obligations remain key factors for investors.
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Shares Bounce 32% But Its Business Still Trails The Industry
Ironwood Pharmaceuticals (NASDAQ:IRWD) shares have recently risen 32%, but its price-to-sales (P/S) ratio of 2.2x is significantly lower than the industry average, indicating potential concerns about its business prospects. The company's revenue has declined by 10% in the last year and 19% over three years. Analysts forecast future revenue growth of 12% per year, which is considerably less than the industry's projected 123% annual expansion, explaining the low P/S ratio.
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
Ironwood Pharmaceuticals (Nasdaq: IRWD) announced its financial guidance for full year 2026, targeting LINZESS U.S. net sales of $1.125 to $1.175 billion, total revenues of $450 to $475 million, and adjusted EBITDA exceeding $300 million. The company is maintaining its FY 2025 financial guidance and ended Q4 2025 with over $200 million in cash. Ironwood also plans to initiate a confirmatory Phase 3 trial for apraglutide in the first half of 2026.
Ironwood Pharmaceuticals Inc. (IRWD) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for Ironwood Pharmaceuticals Inc. (IRWD) stock, showing its current price and daily performance. It also includes sections for analyst ratings, indicating no recent ratings, and a notice about the absence of current earnings information. The page promotes signing up for free trade alerts and offers disclaimers regarding investment advice and potential returns.
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
Ironwood Pharmaceuticals announced its financial guidance for full year 2026, while maintaining its previously issued FY 2025 guidance. The company expects full-year 2026 LINZESS U.S. net sales of $1.125 to $1.175 billion, total revenues of $450 to $475 million, and adjusted EBITDA of greater than $300 million. Ironwood also reported ending Q4 2025 with over $200 million in cash and cash equivalents and is on track to initiate a confirmatory Phase 3 trial for apraglutide in the first half of 2026.
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) announced its financial guidance for full-year 2026, expecting LINZESS U.S. net sales of $1.125 to $1.175 billion, total revenues of $450 to $475 million, and adjusted EBITDA greater than $300 million. The company also confirmed it ended Q4 2025 with over $200 million in cash and cash equivalents and is on track to initiate a confirmatory Phase 3 trial for apraglutide in H1 2026. Ironwood is maintaining its FY 2025 guidance and attributes the anticipated increase in LINZESS net sales for 2026 to a lowered list price and the elimination of inflationary rebates.
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
Ironwood Pharmaceuticals (Nasdaq: IRWD) has reaffirmed its financial guidance for FY 2025 and introduced its guidance for FY 2026, projecting LINZESS® U.S. net sales of $1.125 to $1.175 billion and total revenues of $450 to $475 million for 2026. The company anticipates adjusted EBITDA of over $300 million for 2026 and closed Q4 2025 with more than $200 million in cash. Ironwood also plans to initiate a confirmatory Phase 3 trial for apraglutide in short bowel syndrome with intestinal failure (SBS-IF) in the first half of 2026.
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
Ironwood Pharmaceuticals (Nasdaq: IRWD) has maintained its financial guidance for FY 2025 and announced its guidance for FY 2026, projecting LINZESS U.S. net sales of $1.125 to $1.175 billion, total revenues of $450 to $475 million, and adjusted EBITDA exceeding $300 million for 2026. The company ended Q4 2025 with over $200 million in cash and cash equivalents and is on track to initiate a confirmatory Phase 3 trial for apraglutide in the first half of 2026. Ironwood attributes anticipated increased LINZESS net sales in 2026 to a lowered list price effective January 1, 2026, helping eliminate the inflationary component of statutory required rebates.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Average Recommendation of "Hold" from Brokerages
Ironwood Pharmaceuticals (NASDAQ:IRWD) has received an average "Hold" recommendation from eight brokerages, with a mean 12-month price target of $5.34. The company recently reported strong quarterly earnings, significantly beating analyst expectations for both EPS and revenue. Institutional investors have been increasing their stakes in IRWD, while its shares trade around $3.54 with a market capitalization near $576 million.
Need To Know: Analysts Are Much More Bullish On Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Revenues
Analysts have significantly upgraded their revenue and earnings forecasts for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 2026, leading to a 68% increase in the price target to US$1.85. Despite the market optimism and recent stock price gains, the company's revenue is still projected to decline faster than the wider industry. The report suggests considering the long-term trajectory of earnings rather than just next year's forecasts.
Ironwood (IRWD) Skyrockets 23% as Govt Price for Linzess Falls Within Expectations
Ironwood Pharmaceuticals (IRWD) saw its stock rise over 23% after the U.S. Department of Health and Human Services set the maximum fair price (MFP) for its bowel treatment, Linzess, at $136, a price that aligns with the company's expectations. This new price, effective January 1, 2027, is part of the Inflation Reduction Act to make healthcare more affordable. The company also reported a significant increase in third-quarter net income by 1,013% and a 33.27% jump in revenues, driven by Linzess sales.
Ironwood Pharmaceuticals (IRWD) Price Target Increased by 89.47% to 1.84
The average one-year price target for Ironwood Pharmaceuticals (IRWD) has been increased by 89.47% to $1.84 per share, up from $0.97. Despite this increase from prior estimates, the new average target still represents a decrease of 41.53% from the latest closing price of $3.14 per share. Institutional ownership data shows 338 funds holding positions, with some major shareholders maintaining or increasing their stakes.
There's No Escaping Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Muted Revenues Despite A 39% Share Price Rise
Despite a recent 39% surge in stock price, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) faces challenges with muted revenues, leading to a low price-to-sales (P/S) ratio of 1.1x compared to the biotech industry average. The company's revenue has decreased by 23% in the last year and 26% over three years, with analysts forecasting a further 14% annual decline for the next three years. This outlook suggests that the current P/S ratio reflects investor concerns about future growth, making a significant stock price increase unlikely without a material change in revenue performance.
Need To Know: Analysts Are Much More Bullish On Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Revenues
Analysts have significantly upgraded their revenue and earnings forecasts for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 2026, leading to a substantial increase in the share price. Despite these improvements, the company's revenue is still expected to decline, albeit less severely than previously projected, and at a faster rate than the industry average. The positive revisions have also led to an increased price target, suggesting growing optimism among analysts.
Ironwood Pharmaceuticals (NASDAQ:IRWD investor three-year losses grow to 84% as the stock sheds US$36m this past week
Ironwood Pharmaceuticals (NASDAQ:IRWD) shareholders have experienced an 84% loss over the last three years, despite a 102% gain in the past three months. The company's EPS has also declined to a loss-making position during this period, correlating with the share price drop. While the broader market gained 16% in the last year, Ironwood Pharmaceuticals shareholders lost 65%, compounding a 13% annual loss over five years.
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
Ironwood Pharmaceuticals reported strong Q3 2025 results, with LINZESS U.S. net sales increasing 40% year-over-year to $315 million and GAAP net income reaching $40 million. The company raised its full-year 2025 financial guidance for LINZESS U.S. net sales, total revenue, and adjusted EBITDA, driven by accelerated prescription demand growth and improved net pricing. Ironwood also highlighted the FDA approval of LINZESS for IBS-C in children aged 7 and older and its progress on the apraglutide program.
Inspire Investing LLC Raises Stock Holdings in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Inspire Investing LLC significantly increased its stake in Ironwood Pharmaceuticals (NASDAQ:IRWD) by 138.3% in the second quarter, bringing its total holdings to 552,420 shares. Other institutional investors also raised their positions in the company, which saw its stock decline by 6.6% but reported strong quarterly earnings that exceeded expectations. Ironwood Pharmaceuticals, with a market capitalization of $240.40 million, focuses on developing and commercializing gastrointestinal products.
Ironwood Pharmaceuticals director Andrew Dreyfus to resign effective November 1
Andrew Dreyfus will resign from the Board of Directors of Ironwood Pharmaceuticals, Inc. effective November 1, 2025, due to his appointment as President and CEO of the National Institute for Health Care Management Foundation. The company, which recently changed its auditor from EY to KPMG, noted that his departure was not due to any disagreements. Ironwood Pharmaceuticals (NASDAQ:IRWD) has a market capitalization of $287.51 million.
Ironwood Pharmaceuticals (NASDAQ:IRWD) Rating Increased to Strong-Buy at Zacks Research
Zacks Research has upgraded Ironwood Pharmaceuticals (NASDAQ:IRWD) to a "strong-buy" rating due to increased confidence in the company's stock. This upgrade follows Ironwood Pharmaceuticals' strong financial performance, significantly surpassing analysts' earnings and revenue expectations. Institutional investors are also actively increasing their holdings in the company, indicating growing market interest.
These biotechs are in the market for a buyer
Several Boston-area biotechs are actively seeking "strategic alternatives," such as acquisitions or asset sales, in 2025. Ironwood Pharmaceuticals Inc., for instance, has engaged Goldman Sachs & Co. LLC to explore potential deals. The article suggests that these companies are still on the lookout for buyers or collaborators.
